You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCitalopram
Accession NumberDB00215  (APRD00147)
TypeSmall Molecule
GroupsApproved
DescriptionCitalopram hydrobromide belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Citalopram and its N-demethylated metabolites exist as a racemic mixture but its effects are largely due to the S-enantiomer, S-citalopram and S-demthylcitalopram. Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Citalopram is approved for treatment of depression. Unlabeled indications include mild dementia-associated agitation in nonpsychotic patients, smoking cessation, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy. Citalopram has the fewest drug-drug interactions of the SSRIs.
Structure
Thumb
Synonyms
Citadur
Nitalapram
External Identifiers
  • Lu 10-171
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Abbott-citalopramTablet10 mgOralAbbott Laboratories, Limited2014-03-172015-12-31Canada
Abbott-citalopramTablet20 mgOralAbbott Laboratories, Limited2014-03-122015-12-31Canada
Abbott-citalopramTablet40 mgOralAbbott Laboratories, Limited2014-03-122015-12-31Canada
Accel-citalopram TabletsTablet10 mgOralAccel Pharma Inc2013-03-21Not applicableCanada
Accel-citalopram TabletsTablet20 mgOralAccel Pharma Inc2013-07-02Not applicableCanada
Accel-citalopram TabletsTablet40 mgOralAccel Pharma Inc2013-07-02Not applicableCanada
Act CitalopramTablet30 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
Act CitalopramTablet40 mgOralActavis Pharma Company2004-01-21Not applicableCanada
Act CitalopramTablet20 mgOralActavis Pharma Company2004-01-21Not applicableCanada
Ag-citalopramTablet40 mgOralAngita Pharma Inc.2014-09-14Not applicableCanada
Ag-citalopramTablet10 mgOralAngita Pharma Inc.2014-08-14Not applicableCanada
Ag-citalopramTablet20 mgOralAngita Pharma Inc.2014-09-14Not applicableCanada
Auro-citalopramTablet20 mgOralAuro Pharma Inc2011-11-28Not applicableCanada
Auro-citalopramTablet40 mgOralAuro Pharma Inc2011-11-28Not applicableCanada
Ava-citalopramTablet10 mgOralAvanstra Inc2011-11-232014-08-21Canada
Bio-citalopramTablet40 mgOralBiomed Pharma2016-07-29Not applicableCanada
Bio-citalopramTablet10 mgOralBiomed Pharma2016-07-29Not applicableCanada
Bio-citalopramTablet20 mgOralBiomed Pharma2016-07-29Not applicableCanada
CelexaTablet, film coated40 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-17Not applicableUs
CelexaTablet20 mg/1OralPhysicians Total Care, Inc.2000-11-28Not applicableUs
CelexaTablet, film coated10 mg/1OralAllergan Usa, Inc.1998-07-17Not applicableUs
CelexaTablet40 mg/1OralPhysicians Total Care, Inc.2001-09-05Not applicableUs
CelexaTablet, film coated20 mg/1OralAllergan Usa, Inc.1998-07-17Not applicableUs
CelexaTablet10 mg/1OralPhysicians Total Care, Inc.2004-01-30Not applicableUs
CelexaTablet, film coated40 mg/1OralAllergan Usa, Inc.1998-07-17Not applicableUs
Celexa 10 mgTablet10 mgOralLundbeck Canada IncNot applicableNot applicableCanada
Celexa 20 mgTablet20 mgOralLundbeck Canada Inc1999-03-08Not applicableCanada
Celexa 40 mgTablet40 mgOralLundbeck Canada Inc1999-03-08Not applicableCanada
CitalopramTablet40 mgOralMylan Pharmaceuticals Ulc2009-10-222012-10-19Canada
CitalopramTablet40 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
CitalopramTablet10 mgOralMeliapharm Inc2009-02-262014-06-26Canada
CitalopramTablet10 mgOralSivem Pharmaceuticals Ulc2012-06-14Not applicableCanada
CitalopramTablet10 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
CitalopramTablet20 mgOralSanis Health Inc2010-07-30Not applicableCanada
CitalopramTablet20 mgOralJamp Pharma Corporation2014-09-10Not applicableCanada
CitalopramTablet20 mgOralMeliapharm Inc2009-02-262014-06-25Canada
CitalopramTablet20 mgOralSivem Pharmaceuticals Ulc2012-06-14Not applicableCanada
CitalopramTablet40 mgOralSanis Health Inc2010-07-30Not applicableCanada
CitalopramTablet20 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
CitalopramTablet10 mgOralJamp Pharma Corporation2014-09-10Not applicableCanada
CitalopramTablet40 mgOralMeliapharm Inc2009-02-262014-06-25Canada
CitalopramTablet20 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
CitalopramTablet40 mgOralSivem Pharmaceuticals Ulc2012-06-14Not applicableCanada
CitalopramTablet40 mgOralJubilant Generics LimitedNot applicableNot applicableCanada
CitalopramTablet40 mgOralJamp Pharma Corporation2014-09-10Not applicableCanada
CitalopramTablet10 mgOralSanis Health Inc2015-10-14Not applicableCanada
CitalopramTablet20 mgOralMylan Pharmaceuticals Ulc2009-10-222012-10-19Canada
Citalopram TabletsTablet20 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Citalopram TabletsTablet40 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Citalopram Tablets USPTablet40 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Citalopram Tablets USPTablet10 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Citalopram Tablets USPTablet20 mgOralTorrent Pharmaceuticals LimitedNot applicableNot applicableCanada
Citalopram-10Tablet10 mgOralPro Doc Limitee2009-06-25Not applicableCanada
Citalopram-20Tablet20 mgOralPro Doc Limitee2004-12-06Not applicableCanada
Citalopram-40Tablet40 mgOralPro Doc Limitee2004-12-06Not applicableCanada
Citalopram-odanTablet40 mgOralOdan Laboratories Ltd2008-05-082015-11-10Canada
Citalopram-odanTablet20 mgOralOdan Laboratories Ltd2008-05-082015-11-10Canada
Ctp 30Tablet30 mgOralSunovion Pharmaceuticals Canada Inc2007-10-31Not applicableCanada
Dom-citalopramTablet40 mgOralDominion Pharmacal2004-02-06Not applicableCanada
Dom-citalopramTablet10 mgOralDominion Pharmacal2006-02-21Not applicableCanada
Dom-citalopramTablet20 mgOralDominion Pharmacal2004-02-06Not applicableCanada
Ecl-citalopramTablet10 mgOralEcl Pharma Group Ltd2014-10-20Not applicableCanada
Ecl-citalopramTablet20 mgOralEcl Pharma Group Ltd2014-10-20Not applicableCanada
Ecl-citalopramTablet40 mgOralEcl Pharma Group Ltd2014-10-20Not applicableCanada
Ipg-citalopramTablet40 mgOralInternational Pharmaceutical Generics Ltd2008-06-26Not applicableCanada
Ipg-citalopramTablet10 mgOralInternational Pharmaceutical Generics LtdNot applicableNot applicableCanada
Ipg-citalopramTablet20 mgOralInternational Pharmaceutical Generics Ltd2008-06-26Not applicableCanada
Jamp-citalopramTablet20 mgOralJamp Pharma Corporation2008-09-12Not applicableCanada
Jamp-citalopramTablet10 mgOralJamp Pharma Corporation2011-10-06Not applicableCanada
Jamp-citalopramTablet40 mgOralJamp Pharma Corporation2008-09-12Not applicableCanada
Manda-citalopramTablet20 mgOralManda Pharma Inc2012-06-012013-08-22Canada
Manda-citalopramTablet40 mgOralManda Pharma Inc2012-06-012013-08-22Canada
Manda-citalopramTablet10 mgOralManda Pharma Inc2012-07-032013-08-22Canada
Mar-citalopramTablet40 mgOralMarcan Pharmaceuticals Inc2012-09-06Not applicableCanada
Mar-citalopramTablet10 mgOralMarcan Pharmaceuticals Inc2012-09-06Not applicableCanada
Mar-citalopramTablet20 mgOralMarcan Pharmaceuticals Inc2012-09-06Not applicableCanada
Mint-citalopramTablet40 mgOralMint Pharmaceuticals Inc2008-03-10Not applicableCanada
Mint-citalopramTablet20 mgOralMint Pharmaceuticals Inc2015-10-14Not applicableCanada
Mint-citalopramTablet40 mgOralMint Pharmaceuticals Inc2015-10-14Not applicableCanada
Mint-citalopramTablet10 mgOralMint Pharmaceuticals Inc2011-09-13Not applicableCanada
Mint-citalopramTablet20 mgOralMint Pharmaceuticals Inc2008-03-10Not applicableCanada
Mint-citalopramTablet10 mgOralMint Pharmaceuticals Inc2015-10-14Not applicableCanada
Mylan-citalopramTablet40 mgOralMylan Pharmaceuticals Ulc2003-12-19Not applicableCanada
Mylan-citalopramTablet10 mgOralMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Mylan-citalopramTablet20 mgOralMylan Pharmaceuticals Ulc2003-12-19Not applicableCanada
Nat-citalopramTablet10 mgOralNatco Pharma (Canada) Inc2014-02-12Not applicableCanada
Nat-citalopramTablet20 mgOralNatco Pharma (Canada) Inc2014-02-12Not applicableCanada
Nat-citalopramTablet40 mgOralNatco Pharma (Canada) Inc2014-02-12Not applicableCanada
Nat-citalopram TabletsTablet20 mgOralNatco Pharma (Canada) IncNot applicableNot applicableCanada
Nat-citalopram TabletsTablet40 mgOralNatco Pharma (Canada) IncNot applicableNot applicableCanada
Ng CitalopramTablet20 mgOralNext Generation Pharma Inc2009-08-142011-08-30Canada
Ng CitalopramTablet40 mgOralNext Generation Pharma Inc2009-08-142011-08-30Canada
Novo-citalopramTablet20 mgOralNovopharm Limited2004-08-272011-11-08Canada
Novo-citalopramTablet40 mgOralNovopharm Limited2004-08-272011-11-08Canada
Ntp-citalopramTablet10 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-citalopramTablet20 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-citalopramTablet40 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Nu-citalopramTablet20 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-citalopramTablet40 mgOralNu Pharm IncNot applicableNot applicableCanada
Pendo-citalopramTablet20 mgOralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
PHL-citalopramTablet10 mgOralPharmel Inc2006-03-13Not applicableCanada
PHL-citalopramTablet20 mgOralPharmel Inc2004-04-06Not applicableCanada
PHL-citalopramTablet40 mgOralPharmel Inc2004-04-06Not applicableCanada
PMS-citalopramTablet20 mgOralPharmascience Inc2004-01-15Not applicableCanada
PMS-citalopramTablet10 mgOralPharmascience Inc2005-09-10Not applicableCanada
PMS-citalopramTablet40 mgOralPharmascience Inc2004-01-15Not applicableCanada
Priva-citalopramTablet10 mgOralPharmapar IncNot applicableNot applicableCanada
Priva-citalopramTablet20 mgOralPharmapar IncNot applicableNot applicableCanada
Priva-citalopramTablet40 mgOralPharmapar IncNot applicableNot applicableCanada
Q-citalopramTablet10 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-citalopramTablet40 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-citalopramTablet20 mgOralQd Pharmaceuticals Ulc2011-11-242015-08-21Canada
Ran-citaloTablet40 mgOralRanbaxy Pharmaceuticals Canada Inc.2006-12-07Not applicableCanada
Ran-citaloTablet20 mgOralRanbaxy Pharmaceuticals Canada Inc.2006-12-07Not applicableCanada
Ran-citalopramTablet20 mgOralRanbaxy Pharmaceuticals Canada Inc.2005-07-142010-08-06Canada
Ran-citalopramTablet40 mgOralRanbaxy Pharmaceuticals Canada Inc.2005-07-142010-08-06Canada
Ratio-citalopramTablet40 mgOralTeva Canada Limited2004-04-262012-12-21Canada
Ratio-citalopramTablet20 mgOralTeva Canada Limited2004-04-262012-12-21Canada
Riva-citalopramTablet40 mgOralLaboratoire Riva Inc2004-03-242013-07-31Canada
Riva-citalopramTablet10 mgOralLaboratoire Riva Inc2008-01-24Not applicableCanada
Riva-citalopramTablet20 mgOralLaboratoire Riva Inc2008-01-28Not applicableCanada
Riva-citalopramTablet40 mgOralLaboratoire Riva Inc2008-01-28Not applicableCanada
Riva-citalopramTablet10 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-citalopramTablet20 mgOralLaboratoire Riva Inc2004-03-242014-07-29Canada
Sandoz CitalopramTablet20 mgOralSandoz Canada Incorporated2004-01-30Not applicableCanada
Sandoz CitalopramTablet40 mgOralSandoz Canada Incorporated2004-01-30Not applicableCanada
Septa-citalopramTablet10 mgOralSepta Pharmaceuticals Inc2015-09-18Not applicableCanada
Septa-citalopramTablet40 mgOralSepta Pharmaceuticals Inc2010-10-15Not applicableCanada
Septa-citalopramTablet20 mgOralSepta Pharmaceuticals Inc2010-10-15Not applicableCanada
Teva-citalopramTablet20 mgOralTeva Canada Limited2007-09-19Not applicableCanada
Teva-citalopramTablet40 mgOralTeva Canada Limited2007-12-03Not applicableCanada
Teva-citalopramTablet10 mgOralTeva Canada Limited2008-12-15Not applicableCanada
Van-citalopramTablet20 mgOralVanc Pharmaceuticals Inc2016-02-01Not applicableCanada
Van-citalopramTablet40 mgOralVanc Pharmaceuticals Inc2016-02-01Not applicableCanada
Van-citalopramTablet10 mgOralVanc Pharmaceuticals Inc2016-02-01Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-citalopramTablet20 mgOralApotex Inc2004-01-21Not applicableCanada
Apo-citalopramTablet40 mgOralApotex Inc2004-01-21Not applicableCanada
CitalopramTablet20 mg/1OralBlu Pharmaceuticals, LLC2007-04-03Not applicableUs
CitalopramTablet20 mg/1OralAphena Pharma Solutions New Jersey, Llc2010-09-13Not applicableUs
CitalopramTablet20 mg/1OralInternational Labs, Inc.2013-08-01Not applicableUs
CitalopramTablet40 mg/1OralClinical Solutions Wholesale2007-11-08Not applicableUs
CitalopramTablet, film coated40 mg/1OralMylan Pharmaceuticals Inc.2008-07-28Not applicableUs
CitalopramTablet, film coated10 mg/1OralAurobindo Pharma Limited2004-10-28Not applicableUs
CitalopramTablet40 mg/1OralPreferred Pharmaceuticals, Inc.2014-10-17Not applicableUs
CitalopramTablet, film coated10 mg/1OralDIRECT RX2016-03-22Not applicableUs
CitalopramTablet20 mg/1OralPreferred Pharmaceuticals, Inc2011-02-09Not applicableUs
CitalopramTablet40 mg/1OralA S Medication Solutions2011-01-01Not applicableUs
CitalopramTablet40 mg/1OralUnit Dose Services2011-01-01Not applicableUs
CitalopramTablet, film coated10 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
CitalopramTablet20 mg/1OralTeva Pharmaceuticals USA Inc2007-02-222016-02-29Us
CitalopramTablet, film coated10 mg/1OralApotex Corp.2011-08-01Not applicableUs
CitalopramTablet, film coated20 mg/1OralAmerican Health Packaging2014-04-01Not applicableUs
CitalopramTablet20 mg/1OralG&W Laboratories, Inc.2015-12-02Not applicableUs
CitalopramTablet, film coated40 mg/1OralContract Pharmacy Services Pa2010-04-07Not applicableUs
CitalopramTablet20 mg/1OralMc Kesson Contract Packaging2011-09-01Not applicableUs
CitalopramTablet, film coated10 mg/1OralEpic Pharma, LLC2011-05-20Not applicableUs
CitalopramTablet, film coated10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2004-10-28Not applicableUs
CitalopramTablet40 mg/1OralLegacy Pharmaceutical Packaging, Llc2016-07-22Not applicableUs
CitalopramTablet20 mg/1OralRed Pharm Drug, Inc.2011-01-01Not applicableUs
CitalopramTablet40 mg/1OralCamber Pharmaceuticals2011-01-01Not applicableUs
CitalopramTablet, film coated40 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
CitalopramTablet, film coated40 mg/1OralJubilant Cadista Pharmaceuticals Inc.2015-12-23Not applicableUs
CitalopramTablet40 mg/1OralUnit Dose Services2009-01-01Not applicableUs
CitalopramTablet10 mg/1OralAmneal Pharmaceuticals of New York, LLC2010-04-06Not applicableUs
CitalopramTablet20 mg/1OralContract Pharmacy Services Pa2010-06-30Not applicableUs
CitalopramTablet10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2009-01-01Not applicableUs
CitalopramTablet40 mg/1OralLegacy Pharmaceutical Packaging2010-04-30Not applicableUs
CitalopramTablet40 mg/1OralBlenheim Pharmacal, Inc.2010-01-04Not applicableUs
CitalopramTablet20 mg/1OralDIRECT RX2015-01-01Not applicableUs
CitalopramTablet40 mg/1OralAphena Pharma Solutions Tennessee, Llc2011-01-01Not applicableUs
CitalopramTablet, film coated40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2004-10-28Not applicableUs
CitalopramTablet, film coated40 mg/1OralRebel Distributors Corp.2007-03-27Not applicableUs
CitalopramTablet, film coated20 mg/1OralREMEDYREPACK INC.2014-05-28Not applicableUs
CitalopramTablet, film coated40 mg/1OralCardinal Health2013-02-08Not applicableUs
CitalopramTablet, film coated40 mg/1OralEon Labs, Inc.2004-10-28Not applicableUs
CitalopramTablet40 mg/1OralSt Marys Medical Park Pharmacy2014-05-23Not applicableUs
CitalopramTablet10 mg/1OralPreferred Pharmaceuticals Inc.2016-11-07Not applicableUs
CitalopramTablet40 mg/1OralBlu Pharmaceuticals, LLC2007-04-03Not applicableUs
CitalopramTablet40 mg/1OralAphena Pharma Solutions New Jersey, Llc2010-09-13Not applicableUs
CitalopramTablet10 mg/1OralCardinal Health2011-01-19Not applicableUs
CitalopramTablet40 mg/1OralNew Horizon Rx Group, LLC2013-08-25Not applicableUs
CitalopramTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-02-22Not applicableUs
CitalopramTablet40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-11-22Not applicableUs
CitalopramTablet, film coated20 mg/1OralREMEDYREPACK INC.2015-12-24Not applicableUs
CitalopramTablet, film coated20 mg/1OralAurobindo Pharma Limited2004-10-28Not applicableUs
CitalopramTablet, film coated20 mg/1OralContract Pharmacy Services Pa2010-04-06Not applicableUs
CitalopramTablet, film coated20 mg/1OralProficient Rx LP2004-10-28Not applicableUs
CitalopramTablet10 mg/1OralAurolife Pharma LLC2009-01-01Not applicableUs
CitalopramTablet40 mg/1OralTeva Pharmaceuticals USA Inc2007-11-082016-03-31Us
CitalopramTablet, film coated20 mg/1OralApotex Corp.2011-08-01Not applicableUs
CitalopramTablet20 mg/1OralReady Meds2011-01-01Not applicableUs
CitalopramTablet40 mg/1OralMed Vantx, Inc.2012-04-24Not applicableUs
CitalopramTablet10 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-22Not applicableUs
CitalopramTablet10 mg/1OralTeva Pharmaceuticals USA Inc2007-02-222015-11-30Us
CitalopramTablet40 mg/1OralG&W Laboratories, Inc.2015-12-02Not applicableUs
CitalopramTablet40 mg/1OralPd Rx Pharmaceuticals, Inc.2010-09-13Not applicableUs
CitalopramTablet40 mg/1OralMc Kesson Contract Packaging2011-09-22Not applicableUs
CitalopramTablet, film coated20 mg/1OralEpic Pharma, LLC2011-05-20Not applicableUs
CitalopramTablet, film coated20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2004-10-28Not applicableUs
CitalopramTablet10 mg/1OralCipla USA Inc.2016-07-22Not applicableUs
CitalopramTablet, film coated40 mg/1OralPhysicians Total Care, Inc.2007-01-22Not applicableUs
CitalopramTablet10 mg/1OralGolden State Medical Supply, Inc.2011-05-20Not applicableUs
CitalopramTablet, film coated10 mg/1OralMylan Pharmaceuticals Inc.2008-07-28Not applicableUs
CitalopramTablet40 mg/1OralREMEDYREPACK INC.2014-12-15Not applicableUs
CitalopramTablet20 mg/1OralAmneal Pharmaceuticals of New York, LLC2010-04-06Not applicableUs
CitalopramTablet40 mg/1OralContract Pharmacy Services Pa2010-06-30Not applicableUs
CitalopramTablet40 mg/1OralRebel Distributors Corp2011-01-01Not applicableUs
CitalopramTablet, film coated20 mg/1OralBlenheim Pharmacal, Inc.2013-09-30Not applicableUs
CitalopramTablet40 mg/1OralDIRECT RX2015-01-01Not applicableUs
CitalopramTablet20 mg/1OralH.J. Harkins Company, Inc.2009-01-01Not applicableUs
CitalopramTablet40 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
CitalopramTablet, film coated10 mg/1OralCardinal Health2013-02-08Not applicableUs
CitalopramTablet40 mg/1OralREMEDYREPACK INC.2013-03-042017-11-09Us
CitalopramTablet10 mg/1OralCamber Pharmaceuticals2011-01-01Not applicableUs
CitalopramTablet, film coated20 mg/1OralInternational Laboratories, Inc.2008-06-25Not applicableUs
CitalopramTablet20 mg/1OralCardinal Health2011-01-19Not applicableUs
CitalopramTablet, film coated10 mg/1OralJubilant Cadista Pharmaceuticals Inc.2015-12-23Not applicableUs
CitalopramTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-02-22Not applicableUs
CitalopramTablet20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-11-22Not applicableUs
CitalopramTablet20 mg/1OralDIRECT RX2015-01-01Not applicableUs
CitalopramTablet, film coated40 mg/1OralAurobindo Pharma Limited2004-10-28Not applicableUs
CitalopramTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.2010-09-13Not applicableUs
CitalopramTablet, film coated10 mg/1OralAvera Mc Kennan Hospital2015-03-04Not applicableUs
CitalopramSolution10 mg/5mLOralWest Ward Pharmaceuticals Corp2004-05-25Not applicableUs
CitalopramTablet20 mg/1OralAurolife Pharma LLC2009-01-01Not applicableUs
CitalopramTablet, film coated40 mg/1OralPd Rx Pharmaceuticals, Inc.2004-10-28Not applicableUs
CitalopramTablet, film coated10 mg/1OralRebel Distributors Corp.2007-03-27Not applicableUs
CitalopramTablet20 mg/1OralREMEDYREPACK INC.2013-05-08Not applicableUs
CitalopramTablet40 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
CitalopramTablet, film coated10 mg/1OralEon Labs, Inc.2004-10-28Not applicableUs
CitalopramTablet, film coated40 mg/1OralApotex Corp.2011-08-01Not applicableUs
CitalopramTablet40 mg/1OralMed Vantx, Inc.2007-11-08Not applicableUs
CitalopramTablet40 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-01-01Not applicableUs
CitalopramTablet20 mg/1OralAmerican Health Packaging2013-07-252015-12-31Us
CitalopramTablet20 mg/1OralBlenheim Pharmacal, Inc.2010-07-06Not applicableUs
CitalopramTablet20 mg/1OralGolden State Medical Supply, Inc.2011-05-20Not applicableUs
CitalopramTablet, film coated10 mg/1OralRed Pharm Drug Inc.2004-10-28Not applicableUs
CitalopramTablet, film coated20 mg/1OralSafecor Health, LLC2014-09-30Not applicableUs
CitalopramTablet, film coated40 mg/1OralEpic Pharma, LLC2011-05-20Not applicableUs
CitalopramTablet20 mg/1OralCipla USA Inc.2016-07-22Not applicableUs
CitalopramTablet, film coated20 mg/1OralPhysicians Total Care, Inc.2008-01-18Not applicableUs
CitalopramTablet20 mg/1OralClinical Solutions Wholesale2009-01-01Not applicableUs
CitalopramTablet, film coated20 mg/1OralMylan Pharmaceuticals Inc.2008-07-28Not applicableUs
CitalopramTablet40 mg/1OralREMEDYREPACK INC.2013-03-04Not applicableUs
CitalopramTablet, film coated10 mg/1OralREMEDYREPACK INC.2015-07-22Not applicableUs
CitalopramTablet40 mg/1OralAmneal Pharmaceuticals of New York, LLC2010-04-06Not applicableUs
CitalopramTablet40 mg/1OralLegacy Pharmaceutical Packaging, Llc2011-01-01Not applicableUs
CitalopramTablet, film coated20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2004-10-28Not applicableUs
CitalopramTablet, film coated40 mg/1OralBlenheim Pharmacal, Inc.2011-05-20Not applicableUs
CitalopramTablet10 mg/1OralBlu Pharmaceuticals, LLC2007-04-03Not applicableUs
CitalopramTablet10 mg/1OralAphena Pharma Solutions New Jersey, Llc2010-09-13Not applicableUs
CitalopramTablet, film coated40 mg/1OralInternational Laboratories, Inc.2014-01-01Not applicableUs
CitalopramTablet40 mg/1OralAurolife Pharma LLC2009-01-01Not applicableUs
CitalopramTablet40 mg/1OralA S Medication Solutions2011-01-01Not applicableUs
CitalopramTablet, film coated10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2004-10-28Not applicableUs
CitalopramTablet20 mg/1OralCamber Pharmaceuticals2011-01-01Not applicableUs
CitalopramTablet, film coated20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
CitalopramTablet, film coated10 mg/1OralInternational Laboratories, Inc.2008-06-25Not applicableUs
CitalopramTablet40 mg/1OralCardinal Health2011-01-19Not applicableUs
CitalopramTablet, film coated20 mg/1OralJubilant Cadista Pharmaceuticals Inc.2015-12-23Not applicableUs
CitalopramTablet40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-11-08Not applicableUs
CitalopramTablet, film coated40 mg/1OralProficient Rx LP2004-10-28Not applicableUs
CitalopramTablet20 mg/1OralMed Vantx, Inc.2007-02-22Not applicableUs
CitalopramTablet10 mg/1OralMc Kesson Contract Packaging2011-09-22Not applicableUs
CitalopramTablet20 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-01-01Not applicableUs
CitalopramTablet10 mg/1OralAmerican Health Packaging2013-07-252015-12-29Us
CitalopramTablet20 mg/1OralBlenheim Pharmacal, Inc.2010-01-04Not applicableUs
CitalopramTablet, film coated40 mg/1OralREMEDYREPACK INC.2015-05-15Not applicableUs
CitalopramTablet, film coated20 mg/1OralRebel Distributors Corp.2007-03-27Not applicableUs
CitalopramTablet, film coated40 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
CitalopramTablet, film coated20 mg/1OralCardinal Health2013-02-08Not applicableUs
CitalopramTablet40 mg/1OralClinical Solutions Wholesale, Llc2011-01-01Not applicableUs
CitalopramTablet, film coated20 mg/1OralEon Labs, Inc.2004-10-28Not applicableUs
CitalopramTablet10 mg/1OralContract Pharmacy Services Pa2010-06-30Not applicableUs
CitalopramTablet, film coated10 mg/1OralPhysicians Total Care, Inc.2010-01-14Not applicableUs
CitalopramTablet40 mg/1OralGolden State Medical Supply, Inc.2011-05-20Not applicableUs
CitalopramTablet10 mg/1OralG&W Laboratories, Inc.2015-12-02Not applicableUs
CitalopramTablet20 mg/1OralREMEDYREPACK INC.2013-02-252016-10-15Us
CitalopramTablet, film coated10 mg/1OralAmerican Health Packaging2014-04-01Not applicableUs
CitalopramTablet40 mg/1OralCipla USA Inc.2016-07-22Not applicableUs
CitalopramTablet, film coated40 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralMajor Pharmaceuticals2009-11-02Not applicableUs
Citalopram HydrobromideTablet, film coated40 mg/1OralCardinal Health2004-11-24Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralREMEDYREPACK INC.2011-05-16Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralREMEDYREPACK INC.2015-07-27Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralRebel Distributors Corp2007-10-18Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralBlenheim Pharmacal, Inc.2013-10-04Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralApotheca Inc.2007-10-18Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralStat Rx USA2007-10-18Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralREMEDYREPACK INC.2013-03-18Not applicableUs
Citalopram HydrobromideTablet, film coated10 mg/1OralDr. Reddy's Laboratories Limited2004-10-28Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralSun Pharmaceutical Industries, Inc.2015-05-29Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralREMEDYREPACK INC.2011-04-26Not applicableUs
Citalopram HydrobromideTablet10 mg/1Oralbryant ranch prepack2004-11-12Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralMed Vantx, Inc.2007-10-18Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralAidarex Pharmaceuticals LLC2007-10-18Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralExelan Pharmaceuticals Inc.2012-10-01Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralCardinal Health2009-11-02Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.2004-11-12Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralTorrent Pharmaceuticals Limited2007-10-18Not applicableUs
Citalopram HydrobromideSolution10 mg/5mLOralSilarx Pharmaceuticals, Inc2006-06-14Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.2004-11-12Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-18Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralProficient Rx LP2007-10-18Not applicableUs
Citalopram HydrobromideTablet, film coated20 mg/1OralMed Vantx, Inc.2004-10-28Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralClinical Solutions Wholesale2004-11-12Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralREMEDYREPACK INC.2011-07-28Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralPreferred Pharmaceuticals, Inc.2013-03-26Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralA S Medication Solutions2007-10-18Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralInternational Labs, Inc.2012-02-202016-10-13Us
Citalopram HydrobromideTablet40 mg/1OralRebel Distributors Corp2007-10-18Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralPreferred Pharmaceuticals Inc.2016-01-04Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralCardinal Health2009-11-02Not applicableUs
Citalopram HydrobromideSolution10 mg/5mLOralAtlantic Biologicals Corps2006-06-14Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralPd Rx Pharmaceuticals, Inc.2007-10-18Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralStat Rx USA2007-10-18Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralREMEDYREPACK INC.2013-05-06Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Citalopram HydrobromideTablet, film coated20 mg/1OralDr. Reddy's Laboratories Limited2004-10-28Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralSun Pharmaceutical Industries, Inc.2015-05-29Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralREMEDYREPACK INC.2011-06-08Not applicableUs
Citalopram HydrobromideTablet, film coated10 mg/1OralGlenmark Generics Inc., USA2009-02-27Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralNorthwind Pharmaceuticals, LLC2015-02-16Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralProficient Rx LP2007-10-18Not applicableUs
Citalopram HydrobromideTablet, film coated40 mg/1OralMed Vantx, Inc.2004-10-28Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralContract Pharmacy Services Pa2009-09-01Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralTorrent Pharmaceuticals Limited2007-10-18Not applicableUs
Citalopram HydrobromideSolution10 mg/5mLOralCitron Pharma LLC2006-08-28Not applicableUs
Citalopram HydrobromideSolution10 mg/5mLOralCamber Pharmaceuticals, Inc.2015-12-21Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2004-11-12Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-18Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralREMEDYREPACK INC.2011-08-08Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralLegacy Pharmaceutical Packaging2010-10-01Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-10-01Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralMajor Pharmaceuticals2009-11-02Not applicableUs
Citalopram HydrobromideTablet, film coated40 mg/1OralREMEDYREPACK INC.2010-12-16Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralClinical Solutions Wholesale2004-11-12Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralPreferred Pharmaceuticals, Inc.2013-03-26Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralA S Medication Solutions2007-10-18Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralContract Pharmacy Services Pa2010-07-01Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralSt Marys Medical Park Pharmacy2014-01-23Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralDIRECT RX2014-01-01Not applicableUs
Citalopram HydrobromideTablet, film coated40 mg/1OralDr. Reddy's Laboratories Limited2004-10-28Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralClinical Solutions Wholesale, Llc2007-10-18Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralREMEDYREPACK INC.2011-07-22Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralTYA Pharmaceuticals2007-10-18Not applicableUs
Citalopram HydrobromideTablet, film coated20 mg/1OralGlenmark Generics Inc., USA2009-02-27Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-18Not applicableUs
Citalopram HydrobromideTablet40 mg/301OralNorthwind Pharmaceuticals2014-04-03Not applicableUs
Citalopram HydrobromideTablet20 mg/1Oralbryant ranch prepack2004-11-12Not applicableUs
Citalopram HydrobromideTablet, film coated40 mg/1OralMed Vantx, Inc.2004-10-28Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralExelan Pharmaceuticals Inc.2012-10-01Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralTorrent Pharmaceuticals Limited2007-10-18Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralApotheca Inc.2007-10-18Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralAidarex Pharmaceuticals LLC2007-10-18Not applicableUs
Citalopram HydrobromideTablet, film coated20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2004-11-12Not applicableUs
Citalopram HydrobromideTablet, film coated20 mg/1OralCardinal Health2004-11-24Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralContract Pharmacy Services Pa2010-07-01Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralRebel Distributors Corp2007-10-18Not applicableUs
Citalopram HydrobromideSolution10 mg/5mLOralAurobindo Pharma Limited2006-08-28Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralA S Medication Solutions2007-10-18Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralMajor Pharmaceuticals2009-11-02Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralREMEDYREPACK INC.2008-07-28Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralREMEDYREPACK INC.2016-02-10Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralUnit Dose Services2007-10-18Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralContract Pharmacy Services Pa2010-07-01Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralPd Rx Pharmaceuticals, Inc.2004-11-12Not applicableUs
Citalopram HydrobromideTablet, film coated40 mg/1OralGlenmark Generics Inc., USA2009-02-27Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.2007-10-18Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralDIRECT RX2014-01-01Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralREMEDYREPACK INC.2014-02-20Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralREMEDYREPACK INC.2011-07-25Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralSt Marys Medical Park Pharmacy2007-10-18Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralTYA Pharmaceuticals2004-11-12Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralSun Pharmaceutical Industries, Inc.2015-05-29Not applicableUs
Citalopram HydrobromideTablet40 mg/1Oralbryant ranch prepack2004-11-12Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralMed Vantx, Inc.2007-10-18Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralREMEDYREPACK INC.2011-04-20Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralExelan Pharmaceuticals Inc.2012-10-01Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralCardinal Health2009-11-02Not applicableUs
Citalopram HydrobromideTablet10 mg/1OralStat Rx USA2007-10-18Not applicableUs
Citalopram HydrobromideTablet40 mg/1OralApotheca Inc.2007-10-18Not applicableUs
Citalopram HydrobromideTablet20 mg/1OralAidarex Pharmaceuticals LLC2007-10-18Not applicableUs
Perrigo CitalopramTablet20 mg/1OralContract Pharmacy Services Pa2010-02-25Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AkarinNot Available
CelapramNot Available
CiazilNot Available
CiliftNot Available
CipramNot Available
CipramilNot Available
CiprapineNot Available
CitabaxNot Available
CitalecNot Available
CitolNot Available
CitopamNot Available
CitoxNot Available
CitrolNot Available
DalsanNot Available
ElopramNot Available
HumorupNot Available
OropramNot Available
PramcitNot Available
RecitalNot Available
SeropramNot Available
TalamNot Available
TalohexalNot Available
TemperaxNot Available
VodelaxNot Available
ZentiusNot Available
ZetaloNot Available
Brand mixtures
NameLabellerIngredients
Sentralopram Am-10Physician Therapeutics Llc
Salts
Name/CASStructureProperties
Citalopram Hydrobromide
59729-32-7
Thumb
  • InChI Key: WIHMBLDNRMIGDW-UHFFFAOYNA-N
  • Monoisotopic Mass: 404.089954188
  • Average Mass: 405.304
DBSALT000027
Categories
UNII0DHU5B8D6V
CAS number59729-33-8
WeightAverage: 324.3919
Monoisotopic: 324.163791509
Chemical FormulaC20H21FN2O
InChI KeyWSEQXVZVJXJVFP-UHFFFAOYSA-N
InChI
InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
IUPAC Name
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
SMILES
CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Pharmacology
IndicationFor the treatment of depression. Unlabeled indications include: treatment of mild dementia-associated agitation in nonpsychotic patients, smoking cessation, ethanol abuse, obsessive-compulsive disorder (OCD) in children, and diabetic neuropathy.
Structured Indications
PharmacodynamicsCitalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of citalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. In vitro studies show that citalopram is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Citalopram has no significant affinity for adrenergic (α1, α2, β), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of citalopram was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Citalopram does not inhibit monoamine oxidase.
Mechanism of actionThe antidepressant, antiobsessive-compulsive, and antibulimic actions of citalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Citalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent serotonin transporterProteinyes
inhibitor
HumanP31645 details
Histamine H1 receptorProteinunknown
binder
HumanP35367 details
Alpha-1A adrenergic receptorProteinunknown
binder
HumanP35348 details
Muscarinic acetylcholine receptor M1Proteinunknown
binder
HumanP11229 details
Related Articles
AbsorptionRapidly and well absorbed from the GI tract. Peak plasma concentrations occur within 4 hours of a single orally administered dose. Bioavailability is 80% following oral administration. Food does not affect absorption.
Volume of distribution
  • 12 L/kg
    Citalopram is highly lipophilic and likely widely distributed throughout the body, including the blood-brain-barrier. However, its metabolite, demethylcitalopram does not cross the barrier well.
Protein bindingCitalopram, dimethylcitalopram, and didemethylcitalopram is 80% bound to plasma proteins.
Metabolism

Citalopram is metabolized mainly in the liver via N-demethylation to its principle metabolite, demethylcitalopram. Other metabolites include didemethylcitalopram, citalopram N-oxide, and a deaminated propionic acid derivative. However, the predominant entity in plasma is unchanged citalopram. Cytochrome P450 (CYP) 3A4 and 2C19 isozymes appear to be principally involved in producing demethylcitalopram. Demethylcitalopram appears to be further N-demethylated by CYP2D6 to didemethylcitalopram. Citalopram metabolites possess little pharmacologic activity in comparison to their parent compound and do not likely contribute to the clinical effect of the drug.

SubstrateEnzymesProduct
Citalopram
Citalopram N-oxideDetails
Citalopram
N-DesmethylcitalopramDetails
Citalopram
Not Available
Citalopram propionic acidDetails
N-Desmethylcitalopram
N,N-DidesmethylcitalopramDetails
Route of elimination12-23% of an oral dose of citalopram is recovered unchanged in the urine, while 10% of the dose is recovered in the feces.
Half life35 hours
Clearance

The systemic clearance of citalopram was 330 mL/min, with approximately 20% of that due to renal clearance.

ToxicitySymptoms most often accompanying citalopram overdose, alone or in combination with other drugs and/or alcohol, included dizziness, sweating, nausea, vomiting, tremor, somnolence, and sinus tachycardia. In more rare cases, observed symptoms included amnesia, confusion, coma, convulsions, hyperventilation, cyanosis, rhabdomyolysis, and ECG changes (including QTc prolongation, nodal rhythm, ventricular arrhythmia, and very rare cases of torsade de pointes). Acute renal failure has been very rarely reported accompanying overdose. Withdrawal symptoms include flu-like symptoms, insomnia, nausea, imbalance, sensory changes and hyperactivity.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Citalopram Action PathwayDrug actionSMP00424
Citalopram Metabolism PathwayDrug metabolismSMP00627
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Multidrug resistance protein 1
Gene symbol: ABCB1
UniProt: P08183
rs2032583 Not AvailableC AlleleImproved response to antidepressant medication17913323
5-hydroxytryptamine receptor 2A
Gene symbol: HTR2A
UniProt: P28223
rs7997012 Not AvailableA AlleleImproved response to antidepressant medication16642436
Glutamate receptor ionotropic, kainate 4
Gene symbol: GRIK4
UniProt: Q16099
rs1954787 Not AvailableC AlleleImproved response to antidepressant medication17671280
5-hydroxytryptamine receptor 1A
Gene symbol: HTR1A
UniProt: P08908
rs6295 Not AvailableG AlleleHomozygosity for the rs6295 G allele is associated with lower response rate in patients treated for major depression19829169
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Glutamate receptor ionotropic, kainate 2
Gene symbol: GRIK2
UniProt: Q13002
rs2518224 Not AvailableC Allele, homozygoteIncreased suicidal thoughts17898344
Glutamate receptor 3
Gene symbol: GRIA3
UniProt: P42263
rs4825476 Not AvailableG Allele, homozygoteIncreased suicidal thoughts17898344
Cyclic AMP-responsive element-binding protein 1
Gene symbol: CREB1
UniProt: P16220
rs4675690 Not AvailableT AlleleElevated suicide risk17548750
Cyclic AMP-responsive element-binding protein 1
Gene symbol: CREB1
UniProt: P16220
rs7569963 Not AvailableA AlleleElevated suicide risk17548750
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when 1,1,1,2 Tetrafluoroethane is combined with Citalopram.Investigational
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Citalopram.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Citalopram.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Citalopram.Experimental
AbirateroneThe serum concentration of Citalopram can be increased when it is combined with Abiraterone.Approved
AcarboseCitalopram may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Citalopram.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Citalopram.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Citalopram.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Citalopram can be increased when it is combined with Acetaminophen.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Acetophenazine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Citalopram.Approved
Acetylsalicylic acidCitalopram may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Citalopram.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Citalopram.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Citalopram.Approved
AgomelatineThe serum concentration of Agomelatine can be increased when it is combined with Citalopram.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Citalopram.Approved
AlbendazoleThe serum concentration of Citalopram can be increased when it is combined with Albendazole.Approved, Vet Approved
AlbiglutideCitalopram may increase the hypoglycemic activities of Albiglutide.Approved
AldosteroneThe serum concentration of Citalopram can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Citalopram can be increased when it is combined with Alectinib.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Citalopram.Vet Approved
AlfentanilThe serum concentration of Citalopram can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Citalopram.Approved, Vet Approved
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Citalopram.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Citalopram is combined with Almotriptan.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Citalopram.Approved
AlosetronThe metabolism of Alosetron can be decreased when combined with Citalopram.Approved, Withdrawn
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Citalopram.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Citalopram.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Citalopram.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Citalopram.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Citalopram.Approved, Investigational
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Citalopram.Illicit, Withdrawn
Aminohippuric acidThe serum concentration of Citalopram can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Citalopram.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Citalopram.Approved
AmiodaroneCitalopram may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Citalopram is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Citalopram.Approved
AmlodipineThe serum concentration of Citalopram can be increased when it is combined with Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Citalopram.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Citalopram.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Citalopram.Approved, Vet Approved
AmperozideThe risk or severity of adverse effects can be increased when Citalopram is combined with Amperozide.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Citalopram.Approved, Illicit
AmprenavirThe serum concentration of Citalopram can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Citalopram can be increased when it is combined with Amsacrine.Approved
AnagrelideCitalopram may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Citalopram.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Citalopram.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
AprepitantThe serum concentration of Citalopram can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Citalopram.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Citalopram.Approved, Investigational
ArmodafinilThe serum concentration of Citalopram can be increased when it is combined with Armodafinil.Approved, Investigational
Arsenic trioxideCitalopram may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherCitalopram may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Citalopram.Approved
ASA404The metabolism of ASA404 can be decreased when combined with Citalopram.Investigational
AsenapineCitalopram may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Citalopram can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Citalopram can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Citalopram can be increased when it is combined with Atenolol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Citalopram.Approved
AtorvastatinThe serum concentration of Citalopram can be increased when it is combined with Atorvastatin.Approved
AV650The metabolism of AV650 can be decreased when combined with Citalopram.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Citalopram.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Citalopram is combined with Azaperone.Vet Approved
AzelastineThe serum concentration of Citalopram can be increased when it is combined with Azelastine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Citalopram.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Citalopram.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Citalopram.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Citalopram.Illicit
BedaquilineBedaquiline may increase the QTc-prolonging activities of Citalopram.Approved
BendamustineThe metabolism of Bendamustine can be decreased when combined with Citalopram.Approved, Investigational
BendroflumethiazideCitalopram may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Citalopram.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Citalopram is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Citalopram.Approved
BenzocaineThe serum concentration of Citalopram can be increased when it is combined with Benzocaine.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Citalopram.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Citalopram.Approved
BepridilThe serum concentration of Citalopram can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Citalopram.Approved, Vet Approved
BetaxololThe metabolism of Betaxolol can be decreased when combined with Citalopram.Approved
BexaroteneThe serum concentration of Citalopram can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramideBezitramide may increase the serotonergic activities of Citalopram.Experimental, Illicit, Withdrawn
BifeprunoxThe risk or severity of adverse effects can be increased when Citalopram is combined with Bifeprunox.Investigational
BiperidenThe serum concentration of Citalopram can be increased when it is combined with Biperiden.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Citalopram.Approved
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Citalopram.Investigational
BoceprevirThe metabolism of Citalopram can be decreased when combined with Boceprevir.Approved
BortezomibThe serum concentration of Citalopram can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Citalopram can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Citalopram.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Citalopram.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Citalopram.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Citalopram.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Citalopram.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Citalopram is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Citalopram is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Citalopram.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Citalopram.Approved, Withdrawn
BufuralolThe metabolism of Bufuralol can be decreased when combined with Citalopram.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Citalopram.Approved, Investigational
BuprenorphineThe serum concentration of Citalopram can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Citalopram.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Citalopram.Approved
BuspironeBuspirone may increase the serotonergic activities of Citalopram.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Citalopram.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Citalopram.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Citalopram.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Citalopram.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Citalopram.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Citalopram.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Citalopram.Approved
CabergolineThe risk or severity of adverse effects can be increased when Citalopram is combined with Cabergoline.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Citalopram.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Citalopram.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Citalopram.Approved
CandesartanThe serum concentration of Citalopram can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Citalopram can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Citalopram.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Citalopram.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Citalopram.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Citalopram.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Citalopram.Approved
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Citalopram.Approved
CarmustineThe metabolism of Carmustine can be decreased when combined with Citalopram.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Citalopram.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Citalopram.Approved
CarvedilolThe serum concentration of Citalopram can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Citalopram can be increased when it is combined with Caspofungin.Approved
CelecoxibCitalopram may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Citalopram.Approved, Vet Approved
CeritinibThe serum concentration of Citalopram can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Citalopram.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Citalopram.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Citalopram.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Citalopram.Approved, Illicit, Vet Approved
ChloramphenicolThe serum concentration of Citalopram can be increased when it is combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Citalopram.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Citalopram.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Citalopram.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
ChlorothiazideCitalopram may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Citalopram.Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
ChlorpropamideThe serum concentration of Citalopram can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Citalopram can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneCitalopram may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Citalopram.Approved
CholecalciferolThe serum concentration of Citalopram can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Citalopram can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Citalopram can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Citalopram can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Citalopram.Approved
CimetidineThe serum concentration of Citalopram can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Citalopram can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Citalopram.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Citalopram.Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
CisaprideCitalopram may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Citalopram.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Citalopram.Approved
ClemastineThe metabolism of Citalopram can be decreased when combined with Clemastine.Approved
ClenbuterolThe metabolism of Clenbuterol can be decreased when combined with Citalopram.Approved, Vet Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Citalopram.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Citalopram.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Citalopram.Approved, Illicit
ClofazimineThe serum concentration of Citalopram can be increased when it is combined with Clofazimine.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Citalopram.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Citalopram.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Citalopram.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Citalopram.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Citalopram.Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Citalopram resulting in a loss in efficacy.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Citalopram.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Citalopram.Approved, Illicit
ClotrimazoleThe serum concentration of Citalopram can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Citalopram.Approved
CobicistatThe serum concentration of Citalopram can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Citalopram.Approved
CocaineThe metabolism of Citalopram can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Citalopram.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Citalopram.Approved
ColforsinThe serum concentration of Citalopram can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Citalopram can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Citalopram.Approved
CrizotinibCrizotinib may increase the QTc-prolonging activities of Citalopram.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Citalopram.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Citalopram.Approved
CyclophosphamideThe serum concentration of Citalopram can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Citalopram can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe therapeutic efficacy of Citalopram can be decreased when used in combination with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Citalopram can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Citalopram.Approved
DabrafenibThe serum concentration of Citalopram can be decreased when it is combined with Dabrafenib.Approved
DacarbazineThe metabolism of Dacarbazine can be decreased when combined with Citalopram.Approved, Investigational
DaclatasvirThe serum concentration of Citalopram can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Citalopram can be increased when it is combined with Dactinomycin.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Citalopram.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Citalopram.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Citalopram is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Citalopram.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Citalopram.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Citalopram.Approved, Investigational
DarunavirThe serum concentration of Citalopram can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Citalopram.Approved
DasatinibThe serum concentration of Citalopram can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Citalopram can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Citalopram.Approved
DeferasiroxThe serum concentration of Citalopram can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Citalopram.Approved
DelavirdineThe serum concentration of Citalopram can be increased when it is combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Citalopram.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Citalopram.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Citalopram.Approved
DesloratadineThe serum concentration of Citalopram can be increased when it is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Citalopram is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Citalopram is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Citalopram.Vet Approved
DexamethasoneThe serum concentration of Citalopram can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Citalopram.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Citalopram.Approved, Illicit, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Citalopram.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Citalopram.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Citalopram.Approved, Illicit
DextromethorphanCitalopram may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Citalopram.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Citalopram.Approved, Illicit, Withdrawn
DezocineDezocine may increase the serotonergic activities of Citalopram.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Citalopram.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Citalopram can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolCitalopram may increase the anticoagulant activities of Dicoumarol.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Citalopram.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Citalopram.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Citalopram.Approved
DigoxinThe serum concentration of Citalopram can be decreased when it is combined with Digoxin.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Citalopram.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Citalopram is combined with Dihydroergotamine.Approved
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Citalopram.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Citalopram.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Citalopram.Illicit
DiltiazemThe metabolism of Citalopram can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Citalopram.Approved
DinoprostoneThe metabolism of Dinoprostone can be decreased when combined with Citalopram.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Citalopram.Approved
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Citalopram.Approved, Illicit
DipyridamoleThe serum concentration of Citalopram can be increased when it is combined with Dipyridamole.Approved
DisopyramideCitalopram may increase the QTc-prolonging activities of Disopyramide.Approved
DisulfiramThe metabolism of Citalopram can be decreased when combined with Disulfiram.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Citalopram.Approved, Investigational
DofetilideDofetilide may increase the QTc-prolonging activities of Citalopram.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Citalopram.Approved
DomperidoneCitalopram may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Citalopram.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Citalopram.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Citalopram.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Citalopram.Approved
DoxazosinThe serum concentration of Citalopram can be increased when it is combined with Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Citalopram.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Citalopram.Approved, Investigational
DoxorubicinThe serum concentration of Citalopram can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Citalopram can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Citalopram.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Citalopram.Investigational
DronabinolThe serum concentration of Citalopram can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneCitalopram may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Citalopram.Experimental, Illicit
DulaglutideCitalopram may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineThe risk or severity of adverse effects can be increased when Citalopram is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Citalopram.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Citalopram.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Citalopram.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Citalopram is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Citalopram.Approved
EfavirenzThe serum concentration of Citalopram can be increased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Citalopram can be increased when it is combined with Elbasvir.Approved
EletriptanThe risk or severity of adverse effects can be increased when Citalopram is combined with Eletriptan.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Citalopram.Approved
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Citalopram.Approved
EmpagliflozinCitalopram may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe serum concentration of Citalopram can be increased when it is combined with Enalapril.Approved, Vet Approved
EncainideThe metabolism of Encainide can be decreased when combined with Citalopram.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Citalopram.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Citalopram.Approved, Vet Approved
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Citalopram.Approved, Investigational
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Citalopram.Approved, Investigational
EnzalutamideThe serum concentration of Citalopram can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Citalopram.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Citalopram is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Citalopram is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Citalopram is combined with Ergotamine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Citalopram.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
EscitalopramCitalopram may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Citalopram can be increased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Citalopram.Investigational
EsomeprazoleThe serum concentration of Citalopram can be increased when it is combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Citalopram.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Citalopram.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Citalopram can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Citalopram can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Citalopram can be decreased when it is combined with Estrone.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Citalopram.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Citalopram.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Citalopram.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Citalopram.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Citalopram.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Citalopram.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Citalopram.Approved
Ethyl biscoumacetateCitalopram may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Citalopram.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Citalopram.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Citalopram.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Citalopram.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Citalopram.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Citalopram.Approved
EtodolacCitalopram may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Citalopram.Approved
EtoperidoneCitalopram may increase the serotonergic activities of Etoperidone.Approved
EtoposideThe serum concentration of Citalopram can be increased when it is combined with Etoposide.Approved
EtoricoxibCitalopram may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Citalopram.Illicit, Vet Approved
EtravirineThe serum concentration of Citalopram can be increased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Citalopram.Approved
ExenatideCitalopram may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Citalopram.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Citalopram.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Citalopram.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Citalopram.Approved
FelodipineThe serum concentration of Citalopram can be increased when it is combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Citalopram is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineCitalopram may increase the serotonergic activities of Fenfluramine.Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Citalopram is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Citalopram.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Citalopram.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Citalopram.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Citalopram.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Citalopram.Approved
FluconazoleFluconazole may increase the QTc-prolonging activities of Citalopram.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Citalopram.Approved, Illicit
FluindioneCitalopram may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Citalopram.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Citalopram.Approved, Illicit
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Citalopram.Approved
FluoxetineThe serum concentration of Citalopram can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolCitalopram may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Citalopram can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Citalopram can be increased when it is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Citalopram is combined with Fluspirilene.Approved
FlutamideThe metabolism of Flutamide can be decreased when combined with Citalopram.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Citalopram.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Citalopram.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Citalopram.Approved
FluvoxamineThe serum concentration of Citalopram can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
FosamprenavirThe metabolism of Citalopram can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Citalopram can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Citalopram.Approved
FosphenytoinThe metabolism of Citalopram can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Citalopram.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Citalopram is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Citalopram.Approved, Vet Approved
Fusidic AcidThe serum concentration of Citalopram can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Citalopram.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Citalopram.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Citalopram.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Citalopram.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Citalopram.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Citalopram.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Citalopram.Approved
GemfibrozilThe serum concentration of Citalopram can be increased when it is combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
GenisteinThe serum concentration of Citalopram can be increased when it is combined with Genistein.Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Citalopram.Investigational
GliclazideThe metabolism of Gliclazide can be decreased when combined with Citalopram.Approved
GlimepirideCitalopram may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideCitalopram may increase the hypoglycemic activities of Glipizide.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Citalopram.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Citalopram.Approved, Illicit
GlyburideThe serum concentration of Citalopram can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Citalopram can be increased when it is combined with Glycerol.Experimental
GoserelinGoserelin may increase the QTc-prolonging activities of Citalopram.Approved
Gramicidin DThe serum concentration of Citalopram can be increased when it is combined with Gramicidin D.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Citalopram.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Citalopram.Withdrawn
GuanabenzThe metabolism of Guanabenz can be decreased when combined with Citalopram.Approved
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Citalopram.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Citalopram.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Citalopram.Approved
HaloperidolHaloperidol may increase the QTc-prolonging activities of Citalopram.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Citalopram.Approved, Vet Approved
HeroinHeroin may increase the serotonergic activities of Citalopram.Approved, Illicit
HesperetinThe metabolism of Hesperetin can be decreased when combined with Citalopram.Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Citalopram.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Citalopram.Approved
HydracarbazineHydracarbazine may increase the serotonergic activities of Citalopram.Approved
HydrochlorothiazideCitalopram may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Citalopram.Approved, Illicit
HydrocortisoneThe serum concentration of Citalopram can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideCitalopram may increase the hyponatremic activities of Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Citalopram.Approved, Illicit
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Citalopram.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Citalopram.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Citalopram.Approved
IbutilideCitalopram may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Citalopram.Approved
IdelalisibThe serum concentration of Citalopram can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Citalopram.Approved
IloperidoneCitalopram may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Citalopram can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Citalopram.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Citalopram.Approved, Investigational
IndacaterolIndacaterol may increase the QTc-prolonging activities of Citalopram.Approved
IndalpineCitalopram may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Citalopram.Approved
IndinavirThe serum concentration of Citalopram can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Citalopram can be increased when it is combined with Indomethacin.Approved, Investigational
Insulin AspartCitalopram may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirCitalopram may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineCitalopram may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineCitalopram may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanCitalopram may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproCitalopram may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Citalopram.Approved
Ioflupane I-123Citalopram may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Citalopram.Approved
IproclozideIproclozide may increase the serotonergic activities of Citalopram.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Citalopram.Withdrawn
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Citalopram.Approved, Investigational
IsavuconazoniumThe metabolism of Citalopram can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Citalopram.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
IsoniazidThe serum concentration of Citalopram can be increased when it is combined with Isoniazid.Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Citalopram.Approved
ItraconazoleThe metabolism of Citalopram can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Citalopram.Approved
IvacaftorThe serum concentration of Citalopram can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Citalopram can be increased when it is combined with Ivermectin.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Citalopram.Approved
KetamineThe serum concentration of Citalopram can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Citalopram.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Citalopram.Approved
KetoconazoleThe serum concentration of Citalopram can be increased when it is combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Citalopram.Approved, Nutraceutical
LabetalolThe metabolism of Labetalol can be decreased when combined with Citalopram.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Citalopram.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Citalopram.Approved, Investigational
LanreotideCitalopram may increase the hypoglycemic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Citalopram can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Citalopram.Approved
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Citalopram.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Citalopram.Approved
LenvatinibLenvatinib may increase the QTc-prolonging activities of Citalopram.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Citalopram.Approved, Investigational
LevobupivacaineThe metabolism of Levobupivacaine can be decreased when combined with Citalopram.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Citalopram.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Citalopram.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Citalopram.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Citalopram.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Citalopram is combined with Levomilnacipran.Approved
LevorphanolLevorphanol may increase the serotonergic activities of Citalopram.Approved
LevothyroxineThe serum concentration of Citalopram can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Citalopram can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Citalopram.Approved
LinezolidLinezolid may increase the serotonergic activities of Citalopram.Approved, Investigational
LiothyronineThe serum concentration of Citalopram can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Citalopram can be decreased when it is combined with Liotrix.Approved
LiraglutideCitalopram may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe serum concentration of Citalopram can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Citalopram.Approved
LithiumLithium may increase the serotonergic activities of Citalopram.Approved
LofentanilLofentanil may increase the serotonergic activities of Citalopram.Illicit
LomefloxacinThe metabolism of Lomefloxacin can be decreased when combined with Citalopram.Approved
LomitapideThe serum concentration of Citalopram can be increased when it is combined with Lomitapide.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Citalopram.Approved
LoperamideThe serum concentration of Citalopram can be increased when it is combined with Loperamide.Approved
LopinavirCitalopram may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe serum concentration of Citalopram can be increased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Citalopram.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Citalopram is combined with Lorcaserin.Approved
LosartanThe serum concentration of Citalopram can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Citalopram can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Citalopram is combined with Loxapine.Approved
Lu AA21004Citalopram may increase the serotonergic activities of Lu AA21004.Investigational
LuliconazoleThe serum concentration of Citalopram can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Citalopram can be decreased when it is combined with Lumacaftor.Approved
LumefantrineCitalopram may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibCitalopram may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Citalopram is combined with Lurasidone.Approved
MacitentanThe metabolism of Macitentan can be decreased when combined with Citalopram.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Citalopram.Approved, Vet Approved
MalathionThe metabolism of Malathion can be decreased when combined with Citalopram.Approved, Investigational
MannitolThe serum concentration of Mannitol can be increased when it is combined with Citalopram.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Citalopram.Approved
MebanazineMebanazine may increase the serotonergic activities of Citalopram.Withdrawn
MebendazoleThe serum concentration of Citalopram can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecaserminCitalopram may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Citalopram.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Citalopram.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Citalopram.Approved
Megestrol acetateThe serum concentration of Citalopram can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Citalopram.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Citalopram is combined with Melperone.Approved
MenadioneThe metabolism of Menadione can be decreased when combined with Citalopram.Approved, Nutraceutical
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Citalopram.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Citalopram.Approved, Vet Approved
MeprobamateThe serum concentration of Citalopram can be increased when it is combined with Meprobamate.Approved, Illicit
MequitazineThe metabolism of Mequitazine can be decreased when combined with Citalopram.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Citalopram.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Citalopram.Approved
MetforminCitalopram may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Citalopram.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Citalopram.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Citalopram.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Citalopram.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Citalopram.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Citalopram.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Citalopram.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Citalopram.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Citalopram.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Citalopram.Approved, Vet Approved
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Citalopram.Approved
MethyclothiazideCitalopram may increase the hyponatremic activities of Methyclothiazide.Approved
Methylene blueCitalopram may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Citalopram.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Citalopram.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Citalopram.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Citalopram.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Citalopram.Approved, Illicit, Withdrawn
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Citalopram.Approved, Investigational
MetolazoneCitalopram may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Citalopram.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Citalopram.Approved
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Citalopram.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Citalopram.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Citalopram.Approved
MibefradilThe serum concentration of Citalopram can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Citalopram can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Citalopram can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
MiglitolCitalopram may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Citalopram is combined with Milnacipran.Approved
MinaprineMinaprine may increase the serotonergic activities of Citalopram.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Citalopram.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Citalopram.Approved
MitomycinThe serum concentration of Citalopram can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Citalopram can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Citalopram can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe serum concentration of Citalopram can be increased when it is combined with Moclobemide.Approved
ModafinilThe serum concentration of Citalopram can be increased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Citalopram.Approved
MolindoneThe risk or severity of adverse effects can be increased when Citalopram is combined with Molindone.Approved
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Citalopram.Approved, Withdrawn
MorphineThe serum concentration of Citalopram can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Citalopram.Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Citalopram.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Citalopram.Approved, Investigational
NabumetoneCitalopram may increase the antiplatelet activities of Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Citalopram.Approved
NafcillinThe serum concentration of Citalopram can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Citalopram.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Citalopram.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Citalopram.Approved, Vet Approved
NaltrexoneThe serum concentration of Citalopram can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Citalopram.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Citalopram is combined with Naratriptan.Approved, Investigational
NaringeninThe serum concentration of Citalopram can be increased when it is combined with Naringenin.Experimental
NateglinideThe metabolism of Nateglinide can be decreased when combined with Citalopram.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Citalopram.Approved, Investigational
NefazodoneThe metabolism of Citalopram can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Citalopram can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Citalopram can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Citalopram can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Citalopram can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Citalopram.Withdrawn
NicardipineThe serum concentration of Citalopram can be increased when it is combined with Nicardipine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Citalopram.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Citalopram.Approved
NifedipineThe serum concentration of Citalopram can be decreased when it is combined with Nifedipine.Approved
NilotinibCitalopram may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilutamideThe metabolism of Nilutamide can be decreased when combined with Citalopram.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Citalopram.Approved
NisoldipineThe serum concentration of Citalopram can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Citalopram can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Citalopram can be increased when it is combined with Nitrendipine.Approved
Nitric OxideThe metabolism of Nitric Oxide can be decreased when combined with Citalopram.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Citalopram.Approved, Vet Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Citalopram.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Citalopram.Approved
NorethisteroneThe serum concentration of Citalopram can be decreased when it is combined with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Citalopram.Approved
NormethadoneNormethadone may increase the serotonergic activities of Citalopram.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Citalopram.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Citalopram.Withdrawn
OctreotideOctreotide may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Citalopram.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
OlaparibThe metabolism of Citalopram can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Citalopram.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Citalopram.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Citalopram.Approved
OmeprazoleThe serum concentration of Citalopram can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Citalopram.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Citalopram.Investigational
OpiumOpium may increase the serotonergic activities of Citalopram.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Citalopram.Approved
OsanetantThe risk or severity of adverse effects can be increased when Citalopram is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Citalopram can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Citalopram.Approved
OxaliplatinThe metabolism of Oxaliplatin can be decreased when combined with Citalopram.Approved, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Citalopram.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Oxetacaine is combined with Citalopram.Investigational
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Citalopram.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Citalopram.Approved
OxtriphyllineThe metabolism of Oxtriphylline can be decreased when combined with Citalopram.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Citalopram.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Citalopram.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Citalopram.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
P-NitrophenolThe serum concentration of Citalopram can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Citalopram can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Citalopram can be increased when it is combined with Palbociclib.Approved
PaliperidoneCitalopram may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Citalopram can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronPalonosetron may increase the serotonergic activities of Citalopram.Approved, Investigational
PanobinostatThe serum concentration of Citalopram can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Citalopram can be increased when it is combined with Pantoprazole.Approved
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Citalopram.Approved
ParecoxibCitalopram may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Citalopram.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Citalopram.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Citalopram.Approved
Peginterferon alfa-2bThe serum concentration of Citalopram can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Citalopram.Approved
PentazocinePentazocine may increase the serotonergic activities of Citalopram.Approved, Vet Approved
PentobarbitalThe metabolism of Citalopram can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoxifyllineThe metabolism of Pentoxifylline can be decreased when combined with Citalopram.Approved, Investigational
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Citalopram.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Citalopram.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Citalopram.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Citalopram.Approved
PerindoprilThe serum concentration of Citalopram can be increased when it is combined with Perindopril.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Citalopram.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Citalopram is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Citalopram.Approved
PethidineThe risk or severity of adverse effects can be increased when Citalopram is combined with Pethidine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Citalopram.Withdrawn
PhenelzinePhenelzine may increase the serotonergic activities of Citalopram.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Citalopram.Approved, Withdrawn
PhenindioneCitalopram may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the serotonergic activities of Citalopram.Withdrawn
PhenobarbitalThe metabolism of Citalopram can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Citalopram.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Citalopram.Withdrawn
PhenprocoumonCitalopram may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe metabolism of Citalopram can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Citalopram is combined with Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Citalopram.Approved
PioglitazoneCitalopram may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Citalopram is combined with Pipamperone.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Citalopram.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Citalopram.Approved
PirfenidoneThe serum concentration of Pirfenidone can be increased when it is combined with Citalopram.Investigational
PiritramidePiritramide may increase the serotonergic activities of Citalopram.Investigational
PirlindolePirlindole may increase the serotonergic activities of Citalopram.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Citalopram.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Citalopram.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Citalopram.Approved
Platelet Activating FactorThe serum concentration of Citalopram can be decreased when it is combined with Platelet Activating Factor.Experimental
PodofiloxThe metabolism of Podofilox can be decreased when combined with Citalopram.Approved
PolythiazideCitalopram may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Citalopram.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Citalopram.Approved
PosaconazoleThe metabolism of Citalopram can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideCitalopram may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Citalopram.Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Citalopram.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Citalopram.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Citalopram.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Citalopram.Approved, Vet Approved
PrazosinThe serum concentration of Citalopram can be increased when it is combined with Prazosin.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Citalopram.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Citalopram.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Citalopram.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Pregnanolone is combined with Citalopram.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Citalopram.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Citalopram.Approved
PrimidoneThe metabolism of Citalopram can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Citalopram can be increased when it is combined with Probenecid.Approved
ProcainamideCitalopram may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Citalopram.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Procarbazine.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Citalopram.Approved, Vet Approved
ProgesteroneThe serum concentration of Citalopram can be decreased when it is combined with Progesterone.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Citalopram.Approved
PromazinePromazine may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Citalopram.Approved
PropafenoneThe serum concentration of Citalopram can be increased when it is combined with Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Citalopram.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Propericiazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Citalopram.Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Citalopram.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Citalopram.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Citalopram.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Citalopram is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Citalopram.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Citalopram.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Citalopram.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Citalopram.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Citalopram.Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Citalopram.Approved, Illicit
QuercetinThe serum concentration of Citalopram can be increased when it is combined with Quercetin.Experimental
QuetiapineCitalopram may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe serum concentration of Citalopram can be increased when it is combined with Quinacrine.Approved
QuinethazoneCitalopram may increase the hyponatremic activities of Quinethazone.Approved
QuinidineCitalopram may increase the QTc-prolonging activities of Quinidine.Approved
QuinineCitalopram may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Citalopram.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Citalopram is combined with Raclopride.Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Citalopram.Approved, Investigational
RanitidineThe serum concentration of Citalopram can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Citalopram.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Citalopram.Approved
ReboxetineThe serum concentration of Citalopram can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Citalopram can be increased when it is combined with Regorafenib.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Citalopram.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Citalopram.Approved, Withdrawn
RepaglinideCitalopram may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Citalopram.Investigational
ReserpineThe serum concentration of Citalopram can be decreased when it is combined with Reserpine.Approved
ResveratrolThe metabolism of Resveratrol can be decreased when combined with Citalopram.Experimental, Investigational
RifabutinThe metabolism of Citalopram can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of Citalopram can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Citalopram can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Citalopram.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Citalopram.Approved
RiluzoleThe metabolism of Riluzole can be decreased when combined with Citalopram.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Citalopram.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Citalopram is combined with Ritanserin.Investigational
RitonavirThe metabolism of Citalopram can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Citalopram.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Citalopram is combined with Rizatriptan.Approved
RofecoxibCitalopram may increase the antiplatelet activities of Rofecoxib.Investigational, Withdrawn
RolapitantThe serum concentration of Citalopram can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Citalopram.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Citalopram.Vet Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Citalopram.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Citalopram.Approved
RosiglitazoneCitalopram may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Citalopram.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Citalopram.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Citalopram.Experimental
SafrazineSafrazine may increase the serotonergic activities of Citalopram.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Sage 547 is combined with Citalopram.Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Citalopram.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Citalopram.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
SaxagliptinCitalopram may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe serum concentration of Citalopram can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Citalopram.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Citalopram.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Citalopram.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Citalopram.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Citalopram.Approved, Withdrawn
SertralineThe serum concentration of Citalopram can be increased when it is combined with Sertraline.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
SildenafilThe metabolism of Citalopram can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Citalopram.Approved
SiltuximabThe serum concentration of Citalopram can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Citalopram can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Citalopram can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Citalopram can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Citalopram.Approved, Investigational
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Citalopram.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Citalopram.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Citalopram.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
SotalolCitalopram may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Citalopram.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Citalopram.Experimental
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Citalopram.Experimental
SpironolactoneThe serum concentration of Citalopram can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Citalopram can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Citalopram can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Citalopram can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Citalopram can be decreased when it is combined with Streptozocin.Approved
SufentanilSufentanil may increase the serotonergic activities of Citalopram.Approved, Investigational
SulfadiazineCitalopram may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Citalopram.Approved
SulfinpyrazoneThe serum concentration of Citalopram can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Citalopram is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Citalopram is combined with Sumatriptan.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Citalopram.Approved
TacrineThe serum concentration of Citalopram can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Citalopram.Approved, Investigational
TacrolimusThe serum concentration of Citalopram can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Citalopram resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Citalopram.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Citalopram.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Citalopram is combined with Tapentadol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Citalopram.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Citalopram.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Citalopram.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Citalopram.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Citalopram.Investigational, Withdrawn
TelaprevirThe metabolism of Citalopram can be decreased when combined with Telaprevir.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Citalopram.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Citalopram.Approved
TelmisartanThe serum concentration of Citalopram can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinThe metabolism of Temafloxacin can be decreased when combined with Citalopram.Withdrawn
TemazepamThe metabolism of Temazepam can be decreased when combined with Citalopram.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Citalopram.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Citalopram.Approved
TerazosinThe serum concentration of Citalopram can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Citalopram can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Citalopram.Approved
TerfenadineThe serum concentration of Citalopram can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Citalopram can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Citalopram can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineCitalopram may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Citalopram.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Citalopram.Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Citalopram.Approved, Investigational, Withdrawn
TheobromineThe metabolism of Theobromine can be decreased when combined with Citalopram.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Citalopram.Approved
ThiabendazoleThe metabolism of Thiabendazole can be decreased when combined with Citalopram.Approved, Vet Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Citalopram.Approved, Vet Approved
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Citalopram.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Citalopram.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Citalopram is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Citalopram.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Citalopram.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Citalopram.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Citalopram.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Citalopram.Approved
TiaprideThe risk or severity of adverse effects can be increased when Citalopram is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Citalopram.Approved
TiclopidineThe serum concentration of Citalopram can be increased when it is combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Citalopram.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Citalopram.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Citalopram.Approved
TipranavirThe metabolism of Citalopram can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Citalopram.Approved
TocilizumabThe serum concentration of Citalopram can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Citalopram.Approved, Investigational
TolazamideCitalopram may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Citalopram.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Citalopram.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Citalopram.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Citalopram.Approved
TopiramateThe serum concentration of Citalopram can be increased when it is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Citalopram.Approved, Investigational
ToremifeneCitalopram may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Citalopram.Approved, Investigational
TramadolCitalopram may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Citalopram.Experimental
TranylcypromineThe serum concentration of Citalopram can be increased when it is combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Citalopram.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Citalopram.Approved, Investigational, Nutraceutical
TriamtereneThe metabolism of Triamterene can be decreased when combined with Citalopram.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Citalopram.Approved
TrichlormethiazideCitalopram may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Citalopram can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Citalopram can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Citalopram.Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Citalopram.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Citalopram.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Citalopram.Approved, Vet Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Citalopram.Withdrawn
TroleandomycinThe serum concentration of Citalopram can be increased when it is combined with Troleandomycin.Approved
TropisetronTropisetron may increase the serotonergic activities of Citalopram.Investigational
Uc1010The risk or severity of adverse effects can be increased when Uc1010 is combined with Citalopram.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Citalopram.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Citalopram.Approved
ValdecoxibCitalopram may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Citalopram.Approved, Investigational
VandetanibCitalopram may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Citalopram.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Citalopram.Approved
VemurafenibCitalopram may increase the QTc-prolonging activities of Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Citalopram.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Citalopram.Approved
VerapamilThe metabolism of Citalopram can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Citalopram.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Citalopram.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Citalopram is combined with Vilazodone.Approved
VinblastineThe serum concentration of Citalopram can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Citalopram.Approved, Investigational
VincristineThe serum concentration of Citalopram can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Citalopram can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Citalopram.Approved
VoriconazoleThe serum concentration of Citalopram can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Citalopram.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Citalopram is combined with Vortioxetine.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Citalopram.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Citalopram.Vet Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Citalopram.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Citalopram.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Citalopram.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Citalopram.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Citalopram.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Citalopram.Approved, Investigational, Withdrawn
ZimelidineCitalopram may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneCitalopram may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Citalopram.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Citalopram is combined with Zolmitriptan.Approved, Investigational
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Citalopram.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Citalopram.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Citalopram.Approved
ZotepineThe risk or severity of adverse effects can be increased when Citalopram is combined with Zotepine.Approved
ZuclopenthixolCitalopram may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid St.John's Wort.
  • Take without regard to meals.
References
Synthesis Reference

Hans Petersen, “Method for the preparation of citalopram.” U.S. Patent US6229026, issued December, 1992.

US6229026
General References
  1. Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aaes-Jorgensen T, Gram LF: The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther. 1992 Nov;52(5):547-52. [PubMed:1424428 ]
  2. Atmaca M, Kuloglu M, Tezcan E, Semercioz A: The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res. 2002 Dec;14(6):502-5. [PubMed:12494286 ]
  3. Andersen G, Vestergaard K, Riis JO: Citalopram for post-stroke pathological crying. Lancet. 1993 Oct 2;342(8875):837-9. [PubMed:8104273 ]
  4. Clayton A, Keller A, McGarvey EL: Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord. 2006 Mar;91(1):27-32. Epub 2006 Jan 20. [PubMed:16430968 ]
  5. Baumann P: Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol. 1996 Mar;11 Suppl 1:5-11. [PubMed:8732438 ]
  6. Hyttel J, Bogeso KP, Perregaard J, Sanchez C: The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect. 1992;88(2):157-60. [PubMed:1632943 ]
  7. Caccia S: Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet. 1998 Apr;34(4):281-302. [PubMed:9571301 ]
External Links
ATC CodesN06AB04
AHFS Codes
  • 28:16.04.20
PDB EntriesNot Available
FDA labelDownload (148 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9729
Caco-2 permeable+0.6099
P-glycoprotein substrateSubstrate0.7597
P-glycoprotein inhibitor INon-inhibitor0.6361
P-glycoprotein inhibitor IIInhibitor0.9789
Renal organic cation transporterInhibitor0.6993
CYP450 2C9 substrateNon-substrate0.8401
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.5054
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5223
Ames testNon AMES toxic0.7602
CarcinogenicityNon-carcinogens0.7452
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9054 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7735
hERG inhibition (predictor II)Inhibitor0.8994
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Alphapharm party ltd
  • Forest laboratories inc
  • Apotex inc richmond hill
  • Aurobindo pharma ltd inc
  • Roxane laboratories inc
  • Silarx pharmaceuticals inc
  • Biovail laboratories international srl
  • Actavis elizabeth llc
  • Amneal pharmaceuticals ny llc
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Corepharma llc
  • Dr reddys laboratories ltd
  • Epic pharma llc
  • Glenmark generics ltd
  • Invagen pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Matrix laboratories inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Natco pharma ltd
  • Pliva inc
  • Sandoz inc
  • Taro pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Torrent pharmaceuticals ltd
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral20 mg
TabletOral40 mg
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral40 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral40 mg/1
SolutionOral10 mg/5mL
TabletOral40 mg/301
TabletOral30 mg
TabletOral10 mg
Kit
Prices
Unit descriptionCostUnit
Citalopram Hydrobromide 10 mg/5ml Solution 240ml Bottle122.28USD bottle
Celexa 40 mg tablet3.88USD tablet
Celexa 20 mg tablet3.72USD tablet
Celexa 10 mg tablet3.57USD tablet
Citalopram Hydrobromide 40 mg tablet2.89USD tablet
Citalopram Hydrobromide 20 mg tablet2.8USD tablet
Citalopram Hydrobromide 10 mg tablet2.68USD tablet
Citalopram hbr 40 mg tablet2.53USD tablet
Citalopram hbr 20 mg tablet2.43USD tablet
Citalopram hbr 10 mg tablet2.33USD tablet
Celexa 20 mg Tablet1.47USD tablet
Celexa 40 mg Tablet1.47USD tablet
Ctp 30 30 mg Tablet0.99USD tablet
Apo-Citalopram 20 mg Tablet0.82USD tablet
Apo-Citalopram 40 mg Tablet0.82USD tablet
Citalopram 20 mg Tablet0.82USD tablet
Citalopram 40 mg Tablet0.82USD tablet
Citalopram-Odan 20 mg Tablet0.82USD tablet
Citalopram-Odan 40 mg Tablet0.82USD tablet
Co Citalopram 20 mg Tablet0.82USD tablet
Co Citalopram 40 mg Tablet0.82USD tablet
Jamp-Citalopram 20 mg Tablet0.82USD tablet
Jamp-Citalopram 40 mg Tablet0.82USD tablet
Mint-Citalopram 20 mg Tablet0.82USD tablet
Mint-Citalopram 40 mg Tablet0.82USD tablet
Mylan-Citalopram 20 mg Tablet0.82USD tablet
Mylan-Citalopram 40 mg Tablet0.82USD tablet
Ng Citalopram 20 mg Tablet0.82USD tablet
Ng Citalopram 40 mg Tablet0.82USD tablet
Novo-Citalopram 20 mg Tablet0.82USD tablet
Novo-Citalopram 40 mg Tablet0.82USD tablet
Phl-Citalopram 20 mg Tablet0.82USD tablet
Phl-Citalopram 40 mg Tablet0.82USD tablet
Pms-Citalopram 20 mg Tablet0.82USD tablet
Pms-Citalopram 40 mg Tablet0.82USD tablet
Ran-Citalo 20 mg Tablet0.82USD tablet
Ran-Citalo 40 mg Tablet0.82USD tablet
Ran-Citalopram 20 mg Tablet0.82USD tablet
Ran-Citalopram 40 mg Tablet0.82USD tablet
Ratio-Citalopram 20 mg Tablet0.82USD tablet
Ratio-Citalopram 40 mg Tablet0.82USD tablet
Sandoz Citalopram 20 mg Tablet0.82USD tablet
Sandoz Citalopram 40 mg Tablet0.82USD tablet
Pms-Citalopram 10 mg Tablet0.47USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2049368 No2001-10-232011-08-16Canada
CA2353693 No2003-07-222021-07-24Canada
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point182-183 °CNot Available
water solubilitySparingly soluble FDA label
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00588 mg/mLALOGPS
logP3.58ALOGPS
logP3.76ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)9.78ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area36.26 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity94.02 m3·mol-1ChemAxon
Polarizability35.4 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4i-9110000000-5b1fde1b7a58929c7f2dView in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylbutylamines
Direct ParentPhenylbutylamines
Alternative Parents
Substituents
  • Phenylbutylamine
  • Benzonitrile
  • Aralkylamine
  • Halobenzene
  • Fluorobenzene
  • Aryl halide
  • Aryl fluoride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Organoheterocyclic compound
  • Nitrile
  • Carbonitrile
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Eriksson E, Engberg G, Bing O, Nissbrandt H: Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. Neuropsychopharmacology. 1999 Mar;20(3):287-96. [PubMed:10063489 ]
  2. Maines LW, Keck BJ, Smith JE, Lakoski JM: Corticosterone regulation of serotonin transporter and 5-HT1A receptor expression in the aging brain. Synapse. 1999 Apr;32(1):58-66. [PubMed:10188639 ]
  3. Vicentic A, Battaglia G, Carroll FI, Kuhar MJ: Serotonin transporter production and degradation rates: studies with RTI-76. Brain Res. 1999 Sep 11;841(1-2):1-10. [PubMed:10546982 ]
  4. Dugar A, Keck BJ, Maines LW, Miller S, Njai R, Lakoski JM: Compensatory responses in the aging hippocampal serotonergic system following neurodegenerative injury with 5,7-dihydroxytryptamine. Synapse. 2001 Feb;39(2):109-21. [PubMed:11180498 ]
  5. Dutta AK, Fei XS, Beardsley PM, Newman JL, Reith ME: Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters. J Med Chem. 2001 Mar 15;44(6):937-48. [PubMed:11300876 ]
  6. Plenge P, Wiborg O: High- and low-affinity binding of S-citalopram to the human serotonin transporter mutated at 20 putatively important amino acid positions. Neurosci Lett. 2005 Aug 5;383(3):203-8. Epub 2005 Apr 25. [PubMed:15955412 ]
  7. Schloss P, Betz H: Heterogeneity of antidepressant binding sites on the recombinant rat serotonin transporter SERT1. Biochemistry. 1995 Oct 3;34(39):12590-5. [PubMed:7548008 ]
  8. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  9. Zhong H, Hansen KB, Boyle NJ, Han K, Muske G, Huang X, Egebjerg J, Sanchez C: An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant. Neurosci Lett. 2009 Oct 25;462(3):207-12. doi: 10.1016/j.neulet.2009.07.030. Epub 2009 Jul 16. [PubMed:19616061 ]
  10. Rasmussen TN, Plenge P, Bay T, Egebjerg J, Gether U: A single nucleotide polymorphism in the human serotonin transporter introduces a new site for N-linked glycosylation. Neuropharmacology. 2009 Sep;57(3):287-94. doi: 10.1016/j.neuropharm.2009.05.009. Epub 2009 Jun 3. [PubMed:19500602 ]
  11. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Brosen K, Naranjo CA: Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001 Aug;11(4):275-83. [PubMed:11532381 ]
  2. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. [PubMed:10774624 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Brosen K, Naranjo CA: Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001 Aug;11(4):275-83. [PubMed:11532381 ]
  2. Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54. [PubMed:10774624 ]
  3. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  4. Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica. 1998 Dec;28(12):1203-53. [PubMed:9890159 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369 ]
  2. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Putz B, Binder EB, Muller-Myhsok B, Holsboer F: Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008 Jan 24;57(2):203-9. doi: 10.1016/j.neuron.2007.11.017. [PubMed:18215618 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23